News | October 03, 2014

Accreditation for Cardiovascular Excellence (ACE) Selected by CMS to accredit CREST-2 Registry Clinical Sites

CMS selects ACE to accredit CREST-2 Registry clinical sites

October 3, 2014 — The Centers for Medicare & Medicaid Services (CMS) has determined that clinical sites that wish to participate in the newly announced CREST-2 carotid artery stenting (CAS) registry must receive accreditation. Accreditation for Cardiovascular Excellence (ACE) is a designated organization to provide these reviews. The objective of the CREST-2 Registry is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial. Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with CAS performed by experienced and skilled interventionists.

Interventionists' eligibility will be determined by the multi-specialty CREST-2 Interventional Management Committee. Patient eligibility will include patients with conventional or high risk, symptomatic and asymptomatic carotid artery disease. Individual interventionist safety and quality results from the CREST-2 Registry will help guide selection of interventionists for participation in the CREST-2 randomized clinical trial. Enrollment into the CREST-2 Registry will begin in 2014.

"ACE accreditation process demonstrates a program's commitment to achieving the highest standards of care," says Bonnie H. Weiner, M.D., MSEC, MBA, MSCAI, FACC, and ACE's chief medical officer. "ACE is proud to be an organization recognized by CMS to improve quality outcomes by providing expert guidance to facilities seeking accreditation for CAS."

Citing national accreditation and external review as an accepted strategy for program quality assurance, ACE is viewed as the standard-bearer for achieving quality metrics in CAS. ACE delivers unique programs that help facilities comply with documentation to meet Appropriate Use Criteria (AUC) while elevating the performance of interventional catheterization labs by integrating standardized care. The result is a cost-effective program that mitigates risk.

For more information: www.cvexcel.org

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now